All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-07-05T10:38:24.000Z

Avapritinib for the treatment of AdvSM: Latest updates from the PATHFINDER study

Jul 5, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in advanced systemic mastocytosis.


During the European Hematology Association 2024 Hybrid Congress, Andreas Reiter shared 3-year follow up data from the phase II PATHFINDER study of avapritinib for the treatment of patients with advanced systemic mastocytosis (AdvSM)


Key learnings

The overall response and complete response rates were numerically higher in the treatment-naïve setting (87% and 43%, respectively) vs in patients with ≥1 prior systemic therapy (66% and 21%, respectively). 

Median overall survival (OS) was not reached, regardless of AdvSM subtype or treatment history. 

The 36-month OS rate was 75%, with more favorable data for the treatment-naïve vs pre-treated cohort.

No new safety concerns were identified during the follow up period, with most adverse events manageable with dose reduction or interruption.  

Data from PATHFINDER suggest avapritinib as a feasible treatment option in AdvSM, particularly in early lines of therapy. 

  1. Reiter A. Oral Abstract #S224. Avapritinib in patients with advanced systemic mastocytosis (AdvSM): efficacy and safety analysis from the phase 2 pathfinder study with 3-year follow-up. Presented at: EHA 2024 Hybrid Congress; Jun 15, 2024; Madrid, ES. 

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox